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2. ABBREVIATIONS 
APD action potential duration 
APD5O action potential duration at 50% of repolarisation 
APDgo action potential duration at 90% of repolarisation 
RP resting membrane potential 
APA action potential amplitude 
Vmax maximal rate of depolarisation 
ERP effective refractory period 
EAD early afterdepolarisation 
ET 1 endthelin-1 
Ica-L L-type calcium current 
Ito transient outward potassium current 
IK delayed rectifier potassium current 
IKT rapid component of the delayed rectifier potassium current 
IKS slow component of the delayed rectifier potassium current 
IKI inward rectifier potassium current 
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3. BACKGROUND 
Ischaemic heart disease and its complications, among them cardiac arrhythmias and 
ventricular fibrillation, are a common cause of death in developed countries. Although the 
medical technical developement facilitates the use of more invasive antiarrhythmic treatments 
which includes intracardiac defibrillator implantation and transcatheter radioffequency 
ablation, the vast majority of patients are treated with oral or intravenous antiarrhythmic 
drugs. 
In the last decades, class I antiarrhythmic drugs were used most commonly in the 
treatment and prevention of ventricular rythm disturbances. Large trials such as The Cardiac 
arrhythmia supression trial ( CAST I and II) (1) showed an increased mortality rate after long 
term treatment with class I / C antiarrhythmic drugs (flecainide, encainide, morzicine) in 
postinfarction patients. This was explained partly by the supression of impulse conduction at 
normal heart rates due to the depressing effect of the drugs on the fast sodium currents 
(possible proarrhythmic property) and by their negative inotropic action. 
Therefore, the treatment strategy of the ventricular arrhythmias turned towards the 
potassium chanel blocker class III antiarrhythmic drugs, with their action potential duration 
( APD ) and effective refractory period (ERP ) lenghthening properties without influence on 
the conduction velocity. In the SWORD trial though patients treated with oral d-sotalol (a 
class III antiarrhythmic drug) showed increased mortality (2) due to occurrence of life-
threatening ventricular arrhythmias - torsade de pointes (3). Experiments made on 
mammalian heart preparations revealed a significant lenghthening of APD50 and APD90 after 
administration of Sotalol to the tissue bath. This effect was markedly reverse rate dependent 
and was atributed to the Ijo- ( rapid component of the delayed rectifier potassium current) 
blocking property of the drug. This mechanism can facilitate the occurrence of early 
afterdepolarisation ( EAD) and enhanced inhomogeneity of repolarisation causing fatal 
ventricular arrhythmias (4). 
Since the vast majority of experimental data available at present come from studies 
performed on mammalian or diseased human hearts explanted during cardiac transplantation, 
we evaluated the cellular electrophysiological effects of antiarrhythmic drugs on undiseased 
human donor heart preparations. We measured the possible beneficial effects of the 
combination of a class I/B antiarrhythmic drug mexiletine with sotalol aiming to prevent its 
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pharmacologically disadvantageous effect of reverse rate dependent APD prolongation. 
Amiodarone, a potent antianhythnic drug (5), unlike sotalol, has rate independent 
repolarisation lengthening effects in ventricular myocardium along with block of the inward 
natrium channels (6), suggesting that combination of these two properties are not necessarrily 
harmful, since amiodarone has only little proarrhythmic effects. The literature reveals a case 
of ventricular arrhythmia after treatment with erythromycine, an antibiotic agent with potent 
Ikt blocking effect, which was successfully abolished with administration of mexiletine, a 
class I/B antiarrhythmic agent. This encouraged us to study the possible beneficial cellular 
electrophysiological effects of the combination of sotalol and mexiletine (class HI and I/B) on 
the APD in undiseased human myocardial preparations. 
It is worth mentioning that amiodarone, despite its favorable antiarrhythmic properties, 
has some undesirable noncardiac side effects when administrated longterm orally. Therefore 
large effort is made worldwide to develop new antiarrhythmic agents with no or minimal 
proarrhythmic and extracardiac side effects. In such a chemical synthetic program of the Drug 
Reserch Institute new compounds were obtained with combined class I/B and III 
antiarrhythmic properties, structurally different from amiodarone. In this work we also 
described the cellular electrophysiological effects of one of these compounds, GYKI 16638, 
on the action potential of undiseased human ventricular muscle in comparison with sotalol 
and mexiletine. 
The experimental data obtained from mammalian hearts of different species often give 
rise to controversies regarding the effects and mechanisms of action of several compounds. 
Such a relevant example is the case of endothelin, a group of three vasoactive peptides 
released from vascular and endocardial endothelium. From these, endothelin-1 (ET 1) is a 
potent vasoconstrictor which was described to be present in the human pericardial fluidum 
(7,8). The cellular electrophysiological effects of ET 1 are controversal, depending on the 
origine of the cardiac cells. Administrated intrapericardially in a rather high concentration, ET 
1 causes in dog a significant prolongation of APD with EAD and severe ventricular 
arrhythmias (9). On the other hand ET 1 shortens APD by inhibiting L-type calcium current 
( lea ) and activating potassium currents in rabbit and guinea pig cardiac preparatios 
(10,11,12,13,14). Since human data were not available, we investigated the 
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electrophysiological effects of ET1 on L-type ICa, Ito. Ikt and IKi in undiseased left ventricular 
isolated myocardial cells. 
It is obvious that experimental data obtained from undiseased human myocardium is a 
sine qua non condition to fully characterise the effects and mechanisms of action of different 
antiarrhythmic drugs or other compounds, or, at least, to find the mammalian species which 
electrophysiologically resembles the human myocardium. This is true also in the case of the 
slow component of the delayed rectifier potassium current, since I* show species and tissue 
dependent variations. Li et al. described an E4031 insensitive and indapamine sensitive 
current which was attributed to L, (15) but the measurements were performed in the presence 
of BaCh and CdCl2, making the interpretation of the results difficult. We further described 
this slowly activating and relatively fast deactivating current. 
The small amount of experimental data obtained from human myocardium (mostly 
from diseased, cardiomyopatic explanted hearts,) and even less from donor human hearts, 
along with the sometimes controversial results obtained from experiments made on different 
mammalian myocardial tissue, underlines the great value of the electrophysiological and 
pharmacological measurements made on undiseased human myocardium. In the homograft 
program of the Cardiac Surgery Department of the Szeged University we prepare aorta and 
pulmonary valvular conduits for aorta, pulmonary valve replacements or pulmonary valve 
autotransplantations (Ross procedure). The hearts are obstained from beating heart donors. 
The homograft preparation protocol uses only the aortic and pulmonary valvulated conduits, 
the rest of the heart (atrial and ventricular myocardial mass) being destroyed. This raised the 
idea of explanting the hearts in conformity with the transplantation protocol, i.e after 
administration of cold myocardial protective solutution in the coronary arteries, thus 
preserving entirely for 6 hours the mechanic and electrophysiologic properties of the 
undiseased donor heart. This protocol was approved by the Ethical Review Board of the 
Szeged Medical University (No. 51-57/1997 OEj). 
Aims of the study: 
1.Preservation of myocardium from beating heart donors not used for cardiac 
transplantation 
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2. To investigate the cellular electrophysiological effects of sotalol, mexiletine and a 
new antiarrhythmic compound, GYKI 16638, on undiseased human right ventricular papillary 
and trabecular muscle preparations. 
3. To investigate the properties (amplitudes, activation-deactivation kinetics, drug 
sensitivities) of the slow component of the delayed rectifier potassium current on myocardial 
cells isolated from healthy human hearts. 
4. To study the effect of endothelin-1 on calcium and potassim currents in ventricular 
myocytes obtained from undiseased human donor hearts. 
4. METHODS 
4.1 EXPLANTATION OF THE UNDISEASED DONOR HEART. 
After the brain death of the patient is established sternotomy, along with a xiphopubian 
laparotomy is performed. The abdominal aorta and inferior vena cava along with the two 
kidneys (and liver, pancreas when needed) were safely prepared and the canula for kidney 
perfusion is inserted in the abdominal aorta (thus, in case of hemodynamic instability of the 
donor, the kidneys can be safely explanted). An inverted ,,T" pericardotomy is performed and 
the heart is suspended is a pericardial craddle. Since the only contraindication for homograft 
preparation is the advanced age of the donor (over 60 years) no hearts out of 16 were 
excluded. An aortic root cardioplegic needle was inserted is the ascendent aorta. Inferior and 
superior vena cava and the right superior pulmonary vein were prepared. The donor was fully 
heparinised (with iv-Na heparin). After the kidney perfusion was started, the two vena cava 
were clamped, the right superior pulmonary vena was cut and the heart was allowed to empty 
for three four beats. Then the aorta was crossclamped and 1000 ml of cold (2-4 C°) St. 
Thomas cardioplegic solution was administrated in the aortic root, and the hearts stopped in 
diastole (figl). After explanation the hearts were divided in two parts: the basal region with 
the aortic and pulmonary valvular conduits (for homograft preparation), and the left and right 
ventricular myocardial mass along with parts of the left and right atria. Both parts were 
transported in cold cardioplegic solution (composition in. mM: NaCl 110, KC116, MgCk 16, 
10 
CaCl2 12, NaHCCb 10) to the homograft and experimental laboratories. The experimental 
protocol complied with the declaration of World Medical Association proclaimed in Helsinki 
and was approved by the Ethical Review Board of the Universsity ot Szeged (No. : 51-
57/1997 OEj). 
Fig.l. Explanted heart after cardioplegia. 
Right venticular trabecular and papillary muscles were prepared and used for cellular 
electrophysiological measurements, with the conventional microelectrode technique. Left 
ventricular portions with their intact coronary arteries were isolated and enzimatcally 
digested for obtaining isolated human myocardial cells. 
The time interval between crossclamping of the aorta and begining of the experiments was 5-
12 hours.The donors had no documented cardiac diseases and received no other medication 
than Dopamine, Furosemide or plasma expanders. 
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4.2. CONVENTIONAL MICROELECTRODE TECHNIQUE 
16 preparations were used from 16 donors, mean age 40 ± 0.3, 8 females and 8 males. The 
trabecular and thin (<2mm) papillary muscle preparations were excised and mounted in a 
tissue chamber (50 ml volume) filled with oxygenated (95 % O2, 5 % CO2) modified Tyrode's 
solution containing in mM: NaCL 115, KCL 4, CaCL21,8 MgCL21, NaHC03 20 and glucose 
11. The experiments were performed at 37° C, at a pH between 7,35 and 7,45. 
Each preparation was initially stimulated at a basic cycle lenght of 1000 ms (frequency = 1 
Hz), using 2 ms long rectangular constant voltage pulses isolated from ground and delivered 
via bipolar platinum electrodes in contact with the preparation by a EMG 4747 type 
stimulator. At least 1 hour was allowed for each preparation to equilibrate while they were 
continuously superfused with the Tyrode's solution: Transmembrane potentials were recorded 
using the conventional microelectrode technique. Microelectrodes filled with 3 M KC1 and 
having tip resistances 5-20 MQ were connected to the input of a high impedance electrometer 
(Biologic VF102), which was referenced to the ground. The resting membrane potential (RP), 
action potential amplitude (APA) and action potential duration (APD) measured at 50 % and 
90 % reporalization (APD50-90) and the maximal rate of depolarisation (Vm a x) , were obtained 
by APES HSE software developed in our Department. The stimulator was also controlled by 
the software. After measuring the action potential parameters (maximal sampling rate = 50 
kHz) at the basic cycle length of 1000 ms, 9 different constant stimulation cycle lengths (300, 
400, 500, 700, 1000, 1500, 2000, 3000, and 5000 ms) were applied. Action potential 
parameters were measured at each cycle length following „quasi steady state" adaptation (25 
beats) to the new pacing cycle length. To determine the recovery (offset) kinetics of Vmax, 
extra stimuli (S2) were applied with gradually increasing coupling interval from the basic 
cycle length (SI-SI) of 1000 ms after every 20th basic stimulus (SI). Diastolic interval was 
determined as a time interval corresponding to the difference between the timing of the extra 
stimulus (S1-S2) and the time point of the APD90 of the preceding basic action potential. 
After control measurements drugs were superfused for 40-60 minutes and measurements were 
repeated. When impalements were lost, reimpalements were attempted. If the new 
impalement deviated more than 5 % from the preceding one, the experiment was excluded 
from the evaluation. D-sotalol (Bristol-Myers Co. Wallingford, CT, USA) and mexiletine 
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(Institute for Drug Research Ltd. Budapest, Hungary) were prepared daily from aqueous stock 
solutions (30 mM and 10 mM) to obtain the final drug concentration in the tissue bath. GYKI 
16638 (DDR Ltd. Budapest, Hungary) was diluted similarly but from 10 mM stock solution 
containing 50 % DMSO. At concentrations less than 0,2 % DMSO did not affect action 
potential parameters established in separate measurements. 
4.3. PATCH CLAMP TECHNIQUE 
4.3.1. Myocardial cell isolation 
Part of the left ventricular myocardium along with its adjacent coronary artery was prepared 
for myocardial cell isolation from 33 patients with a mean age of 42,5±8,95 years, 20 female 
and 13 male. The cells were used for: 
a. Demonstration of . existence and characterisation of the slow component of the delayed 
rectifier potassium current in undiseased human myocardium. 
b. Study of the electrophysiological effects of endothelin-1 on Ca and K currents in 
undiseased human ventricular cells. 
The left venticular wall together with its arterial branch was mounted on a modified 
Langendorff apparatus, where it was perfused through the left anterior descending coronary 
artery according to the following sequence: (1) modified Tyrode solution (containing, in 
mmol/1: NaCl, 135; KC1, 4,7; KH2P04, 1,2; MgS04 1,2; HEPES,10; NaHC03, 4,4; glucose 
10; pH=7,2) for 10 min; (2) Ca2+ -free modified Tyrode solution for 10 min; (3) Ca2+ -free 
modified Tyrode containing collagenase(660 mg/1, type I, Sigma), elastase (45mg/l, type HI, 
Sigma), taurine (50 mmol/1) and bovine albumin (2 g/1, fraction V, fatty acid free, Sigma) for 
45 min; (4) after this step of enzymatic digeston the solution was supplemented with protease 
(120 mg/1, type XIV, Sigma) for a further 40-60 min. Portions of the left ventricular wall, 
which was clearly digested by the enzymes, were cut into small pieces and either stored in KB 
medium, or equilibrated for 15 min in modified Tyrode solution containing 1,25 mmol/1 
CaCl2 and 50 mmol/1 taurine. Single myocytes were obtained from the tissue chunks after 
gentle agitation. The solutions were oxygenated (100 % 0 2 ) and the temperature was 
maintained at 37° C throughout the whole isolation procedure. The cells were allowed to 
sediment for 10 min, then the supernatant was decanted and replaced by fresh solution. 
This procedure was repeated three times. The cells in KB medium were stored at 4° C, while 
those stored in modified Tyrode solution were maintained at 12-14° C before use. 
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4.3.2. Voltage clamp 
Experiments were perfomed on calcium-tolerant cells, which were rod shaped and maintained 
clear cross-striations following exposure to oxygenated Tyrode solution containing (in 
mmol/1): NaCl, 140; KC1, 5,4; CaCl2, 2,5; MgCl2, 1,2; Na2HP04, 0,35; HEPES, 5; 
glucose, 10 at pH 7,4. This solution was supplemented with either 3 mmol/14-aminopyridine 
or 0,25 mmol/1 CdCl2, when measuring calcium or potassium currents, respectively. Suction 
pipettes, fabricated from borosilicate glass (Clark), had tip resistances of 2-3 MQ after filling 
with pipette solution. When measuring potassium currents, the solution composition was (in 
mmol/1): K-aspartate, 100; KC1, 20; Mg-ATP, 5; HEPES, 10; K4BAPTA, 5; glucose, 5. When 
measuring calcium current the pipette solution contained (in mmol/1): KC1,110; KOH, 40; K-
ATP, 3; HEPES, 10; EGTA, 10; tetraethylammonium chloride (TEAC1), 20; glucose, 5; 
GTP, 0,25. The pH of both solutions was adjusted to 7,2 using KOH. Membrane currents 
were recorded at 37° C using an Axopatch-ID amplifier (Axon Instruments) in the whole-cell 
configuration of the pach-clamp technique (10). After establishing a high-resistance (1-10 
GO) seal by gentle suction, the cell membrane beneath the tip of the electrode was disrupted 
by further suction or by applying 1,5-V electrical pulses for 1-5 ms. The series resistance was 
typically 4-8 MQ before compensation (usually 50-80%). Experiments were discarded when 
the series resistance was high or substantially increasing during the measurement. Current 
densities are expressed by current amplitudes normalized to cell capacitance measured using 
10-mV hyperpolarizing pulses applied from -lOmV. Outputs of the clamp amplifier were 
digitalized at 100 kHz using an A/D converter (Digidata-1200, Axon Instruments). Data were 
stored for later analysis. 
4.4 STATISTICAL ANALYSIS 
Results are expressed as mean ±SEM values. Student's t-test for paired data was used to 
determine statistical significance. Changes were considered significant when P was less than 
0,05. 
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5. RESULTS 
5.1. The cellular electrophysiological properties of GYKI 16638 (fig 2). 
The effect of 5 pM GYKI 16638 on the basic action potential parameters was studied at 1 Hz 
stimulatinon frequency and compared with that of 30 pM sotalol and 10 pM mexiletine. 
Results of representative experiments are shown in fig 3, 
° CONTROL A CONTROL 
• CONTROL 
Fig.3. Action potential recordings before and after 30 pM sotalol, 10 pM mexiletine and 5 pM GYKI 16638 
superfusion in undiseased human right ventricular muscle preparations. The stimulation frequency was 1 Hz. 
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and summarized in table 1 : 
Drug n RP APA APD50 APD90 V max 
(mV) (mV) (ms) (ms) (Vis) 
Control 6 -89.7 ± 0.9 H9 .2±2 .0 233.0 ±17.4 301.8 ±19.7 230.8 ±21.3 
Sotalol 6 -88.8 ± l.5 l l 9 . 2 ± 2 . 4 281.0 ±21.0* 387.0 ±27.6» 250.0 ±21.1 
30 a M 
Control 6 -87.7 ± l.O H 3 . 8 ± 1.9 205.0 ± 19.2 271.3 ±24.3 296.2 ± 33.3 
Mexiletine 6 -87.7 ± 0.9 110.8 ± 2.7 186.6 ± 18.2» 254.2 ±22.7» 288.3 ± 28.9 
lOuM 
Control 9 -87.3 ± l.O 114.4 ±2.2 248.6 ±22.0 338.9 ±28.6 289.4 ±11.2 
GYKI-16638 9 -87.1 ± 1.2 111.6 ±2.4 242.6 ±20.9 385.4 ±24.0* 268.2 ± 17.3 
5 nM 
Table 1. The effect of sotalol, mexiletine and GYKI 16638 on the action potential parameters in human right 
ventricular preparations at 1 Hz stimulation frequency. 
GYKI 16638 lengthened APD90 but not APD50, without significantly changing other action 
potential parameters. Sotalol (30 pM) lengthened both APD50 and APD90, while mexiletine 
(10 pM) significantly shortened repolarization measured at both APD50 and APD90. 
The frequency dependent effect of GYKI 16638, sotalol and mexiletine was investigated on 
the APD90 and Vmax in the range of stimulation cycle length between 300 and 5000 ms. 
Results are shown in fig. 4 . 
• 30 MM SOTALOL 
• 5 MM GYKI 16638 
0.3 1 2 3 4 6 
CYCLE LENGTH (s) 
Fig. 4. Frequency dependent effect of sotalol, mexiletine and GYKI 16638 on the action potential duration 
(APD 9 0 ) 
16 
Sotalol (30 pM) increased APD considerably more at long cycle lengths than at short ones, 
i.e. it induced strong reverse rate-dependent APD prolongation. In contrast, mexiletine (10 
pM) shortened APD. This APD shortening was minimal and statistically not significant at 
high stimulation frequencies i.e. at short cycle lengths, while it proved to be significant at 
longer cycle lengths. The magnitude of the APD lengthening effect of GYKI 16638 (5 pM) 
was marked but less than that of sotalol. This APD prolongation, however, unlike that 
induced by sotalol, was apparently independent of the rate of stimulation i.e. the drug elicited 
similar increase of the repolarisation time in the whole range of the studied cycle lengths 
(400-5000 ms). 
The frequency dependent effect of GYKI 16638, sotalol and mexiletine on the V m ax was also 
studied. Sotalol (30 pM), as expected from previous animal studies, did not change 
significantly Vmax at any stimulation cycle lengths (Fig 5 ), while both 10 pM mexiletine and 
5 pM GYKI 16638 exerted rate dependent Vmax depression i.e. the higher stimulation rate was 
associated with more Vmax block (fig 5). 
• 3 0 MM S O T A L O L 
• 5 MM G Y K I 1 6 6 3 8 
A 1 Q M M M E X I L E T I N E 
0.3 1 2 3 4 5 
C Y C L E L E N G T H (s) 
Fig. 5. Frequency dependent effects of sotalol, mexiletine and GYKI 16638 on the maximal rate of 
depolarisation ( V m a x ) 
The characteristics of this frequency dependent Vmax block was very similar with mexiletine 
and GYKI 16638 i.e. both drugs depressed Vmax only at cycle lengths shorter than 1000 paSY-y^o^ 
This rate-dependent VmaX block was the consequence of the slowing of the recovery of SOL, . 
y 
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channels from inactivation, which was studied by applying second stimuli with increasing 
coupling intervals during the diastole from a basic cycle length of 1000 ms. In control 
condition i.e. before drug administration and also after sotalol superfusion, Vmax value 
returned, within 30-40 ms during early diastole, almost to its value characteristic at the basic 
cycle length. In marked contrast, after mexiletine and GYKI 16638 administration the 
recovery of Vmax was considerably delayed and could be characterised with a recovery time 
constant of 310.4±71.5 ms (amplitude 96.9±12.7 V/s, n=6) and 298.6±70.2 ms (amplitude 
74.9±13.7 V/s, n=8), respectively. 
5.2. The slow component of the delayed rectifier potassium current 
Results were obtained from 31 cells from 15 hearts (average 2.1 cells/heart, range 1-4). We 
specifically chose to use only cells with high-quality seals and low, stable series resistance 
(Rs), opting for a smaller number of excellent recordings from each preparation rather than 
more recordings of variable quality. In additional 27 cells we could either not observe IKS or 
the IKS amplitudes were so small that it was difficult to distinguish the current from the noise. 
The applied pulse frequency was 0,1. Hz wich allowed the E-4031 insensitive tail current to 
be fully deactivated. The current was activated with a double exponential time course 
(yfast=22,4 ms, yslow=2388 ms) suggesting that it represented both Ikt and Iks currents. 
Complete block of Ikr by 5 pM E-4031 markedly reduced the amplitude of the tail currents 
and changed its activation to a single exponential (y=1763 ms) with a slow time course 
(fig. 6). 
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Fig. 6. Two components of the delayed rectifier potassium current ( I K ) after application of 5 pM of E-4031. 
Additional superfusion of the cell with 30 pM chromanol 293B, a blocker of IKS, entirely 
abolished this residual tail current suggesting that this current indeed represented IKS (fig 7 ) 
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Fig. 7. The two components of I K in the presence of E-4031 and chromanol 293B. 
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All of the other experiments on IKS therefore, were perfomed in the presence of 1 or 5 pM E-
4031 to completely block IKT, thereby facilitaing the separation of IKs from IKr. Since IKS is 
relatively small, and other currents (transient outward, non-specific cation, chloride and 
Na+/Ca2+ exchanger currents) could be also activated during depolarizing pulses and during 
the time course of experiments, the tail current after the end of the test pulse was measured to 
assess IKS-
An instantaneous, background-like, outward current was often developed in long lasting (45-
90 min) measurements (see fig 6,7). This may represent a current activated because of the 
dialysis between the pipette and the intracellular milieu. 
Control 
5500 (ms) 
100 pA 
2000 ms 
Fig. 8. Representative current traces in the presence of E-4031 under control conditions. 
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Fig. 9. Current trace after application of 100 nM L-735,821. 
Fig 8 and fig 9 show representative current traces in the presence of 1 uM E-4031 under 
control conditions and after application of 100 nM L-735,821 respectively. The IKs tail current 
deactivated rapidly (y=122.4±11.7 ms, from 50 mV, n=19) and was completely eliminated by 
L-735,821, another more specific blocker of IKS (see Fig. 8). 
Currents were studied at a holding potential (HP) of - 40 mV. The cells were 
depolarized with 5000 ms long test pulses between -10 and +50 mV and then clamped back to 
-40 mV. Tail current amplitude was measured as the difference between the peak and the state 
current level at the end of the pulse after returning back to -40 mV HP. To determine the 
activation kinetics of IKS we used the envelope of tails test protocol. From holding potential of 
-40 mV test pulses to 50 mV were applied with increasing duration ranging from 100 to 5000 
ms and the amplitude of the tail currents was measured. 
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Fig. 10. The activation kinetics of I Ks tail current. Original current traces ( l e f t ) and the normalised I Ks tail 
current amplitude as a function of test pulse duration ( r ight) are shown. The activation kinetics of the current 
was studied by using test pulses with gradually icreasing duration at 50 mV ( see inset). 
Fig 10 contains the result of a representative experiment, indicating that activation of the tail 
current was rather slow (903±101 ms at 50 mV, n=14). In some cells, the voltage dependence 
of activation of IKS was also studied. 
The activation kinetics of the tail current measured at -40 mV was apparently not voltage 
dependent in the test range of 10-60 mV (fig. 11, fig 12). 
10 mV 
1000 ms 
Fig. 11. The voltage dependence of the activation and deactivation kinetics of human I Ks at 10 mV ( top ) and 50 
mV (bo t tom) test potentials. 
Voltage (mV) 
Fig. 12. Activation kinetics of I ^ as a function of the test potential measured by envelope of tails protocol ( see 
inset). 
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The voltage dependence of the deactivation kinetics of IKs current was detemined by the 
following protocol: IK.s current was activated by 5 s long test pulse to 50 mV from a holding 
potential of -40 mV. Then the cells were clamped back to different voltages ranging from -50 
to 0 mV. 
«T 400-, 
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-50 mV 
—i 1 « 1 1 r 
-60 -40 -30 -20 -10 0 
Voltage (mV) 
Fig. 13. The voltage dependence of the deactivation kinetics of I K.s determined by using the voltage protocol 
indicated in the inset. 
Fig 14 indicates that the deactivation of IKS tail current was clearly voltage dependent i.e. 
being faster at negative voltages (about 100 ms at -50 mV) and slower at depolarized 
potentials (about 300 ms at 0 mV). 
The reversal potential of IKS was measured by clamping the cells back to voltages between -
100 and 0 mV after a 5000-ms long depolarizing pulse to 50 mV from a holding potential of -
40 mV. The results of a representative experiment are shown in fig. 13. 
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Fig. 14. The reversal potential of human I Ks measured by clamping the cells back to voltages between - 9 0 and -
30 mV after a 5000 ms long depolarising pulse of 50 mV from a holding potential o f - 4 0 mV. The tail current 
was determined as L-735,821 sensitive current. The reversal potential was calculated as the intersection of the 
fitted and the zero current lines. 
The tail current in these measurements was determined as L-735,821 sensitive current 
(subtracting the current traces before and after application of 100 nM L-735,821). In six cells, 
the reversal potential was -81,6±2,8 mV on an average which is close to the K+ equilibrium 
potential suggesting K+ as the main charge carrier. Li et al. (15) reported a relatively large 
(about 200 pA) IKS tail current in myocytes obtained from the right ventricle in failing human 
hearts. In this latter study the extracellular solution contained Cd2+ and Ba2" to block Ica and 
IK.I. These divalent ions, however, markedly alter the kinetics of IK and in particular Ba :+ 
blocks IKI in a voltage-dependent manner. Therefore, in some cells we also measured 'IKS' in 
the presence of 0,5 mM BaCh. 
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Fig. 15. After superfusion of the myocyte with E-4031 and L-735,821 no tail current can be noticed. After 
application of 0.5 mM BaCl2 a slowly developing tail current appears. 
As fig 15 shows, in the presence of the selective blocker of IKT (1 qM E-4031) and IKS 
(100 nM L-735,821), as expected, no tail current was recorded at -40 mV after a step potential 
to +30 mV for various durations. Cells were then exposed to 0,5 mM BaCl2 that elicited a 
slowly developing tail current that resembled IKs, as it was also found in two other cells. 
However, since both IKs and IKT were completely blocked by 100 nM L-735,821 and 1 pM E-
4031 this current could not be due to the activation of IK-
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5.3 The electrophysiological effects of endothelin-1 
5.3.1 Effect ofET-1 on calcium current 
The L-type Ica was measured at a rate of 0,2 Hz using deporalizing voltage pulses of 400 ms 
duration clamped from the holding potential of -40 mV to test potentials increasing from -35 
mV up to +60 mV in 5-mV steps. Families of Ica-L were recorded before and 5 min after ET-1 
treatment. Superfusion with 8 nmol/1 ET-1 significantly decreased Ica-L at all membrane 
potentials studied, (fig. 16). 
-40 -20 0 20 40 60 m V 
Fig. 16. Current-voltage relationship obtained for peak calcium current in control conditions ( squares) and in 
presence of 8 nM endothelin-1 ( triangles ). 
At +5 mV, Ica-L was reduced by ET-1 from 10.2+0.6 to 6.8+0.8 pA/pF (66.7+8.9 % of 
control, P<0,05 n=5). This reduction of peak current was accompanied by a lengthening of 
inactivation. Inactivation of Ica-L was fitted as a sum of two exponentials, with estimated time 
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constants of 12.8±1.1 and 97.4±11 ms at +5 mV in Tyrode solution. Both time constants were 
increased by ET-1: to 17.2±1.2 and 122±9 ms, respectively (fig. 17). 
ET-1 
Fig. 17. Superimposed records of I Ca-L measured at +5 mV before and after endothelin-1 treatment. 
Lengthening of the faster component was statistically significant (P<0,05 n=5), while that of 
the slower component was not. The voltage dependence of steady-state activation and 
inactivation was not altered by ET-1. 
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The effect of ET-1 on peak IcA-L developed rapidly (within 2 min) and was not reversible 
within a 7 min period of supervision with ET-l-free Tyrode solution (fig. 18). 
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Fig. 18. Time course of development and lack of reversibility of endothelin-l's effect on peak I Ca.L. 
ET-1 did not affect the voltage dependence of activation of Ica-f half-activation voltages and 
slope factors, obtained by fitting the activation curves to a two-state Boltzmann model, were 
4.7±0.7 versus -4.9+0.7 mV, and 3.7±0.3 versus 4.1+0.8 mV in absence and presence of ET-
1, respectively, (n=5, N.S.,) (fig. 19). 
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Fig. 19. Voltage dependence of steady-state activation of I Ca-L-
The steady.state inactivation of ICA-L was determined using a paired-pulse protocol. Test 
pulses to +5 mV were preceded by a set of prepulses clamped to various voltages between -55 
and +15 mV. Peak currents measured after these prepulses were normalized to the peak 
current measured after the -55-mV prepulse and plotted against the respective prepulse 
potential. 
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Fig. 20. Steady-state inactivation of I Ca.L determined using a paired-pulse protocol. 
As shown in fig. 20, steady-state inactivation curves, obtained in the absence and presence of 
ET-1, were almost identical (midpoint potentials and slope factors were -19.3±1.2 versus -
21.6±0.7 mV, and 3.45+0.27 versus 3.83±0.63 mV, respectively, n=5, N.S.). 
5. 3. 2. Effect of ET-1 on potassium currents 
Iicr was activated using deporalizing voltage pulses of 1000 ms duration clamped from a 
holding potential of -40 mV to test potentials ranging between -20 and +50 mV. The decaying 
tail current recorded at -40 mV after the end of the test pulse was assessed as IJO- The current 
was fully abolished by 5 pmol/1 E-4031, the selective blocker of ho-. ET-1 significantly 
decreased the amplitude of the tail current at each membrane potential studied, (fig. 21). 
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Fig. 21. Effect of endothelin-1 on the rapid component of the delayed rectifier potassium current in human 
ventricular myocytes. Endothelin-1 almost fully abolished I Kr ( left ). Average tail current amplitudes plotted 
against test potentials before ( diamonds ) and after ( squares ) application of endothelin-l( right ). 
Following depolarization to +40 mV , ET-1 decreased IKT tails from 0.31+0.02 to 0,06+0.02 
pA/pF (20.3 % of control, P<0.05, n=4). 
Transient outward K+ current (It0 )was measured at a rate of 0.2 Hz using deporalizing voltage 
pulses of 400 ms duration clamped from a holding potential of -80 mV to test potentials 
ranging between -10 and +60 mV (Fig. 22). 
32 
< c 
OpA-.S 
i l 
ODA -
100 ms 
UL 
a < 
a 
c 0) 
L . 
U 
3 
ü 
X 
ra 
0) 
CL 
18 i 
16 
14 i 
12 
10 i 
8 
6 
4 
2 
• Control 
•ArET-1 (8 nmol/l) 
•20 0 20 40 60 
Membrane potential (mV) 
Fig. 22. Effect of endothelin-Ion transient outward current ( I t 0) recorded before and 5 min. after administration 
of endothelin-1( left ). Peak amplitudes of It0 are plotted against test pulse potentials ( right ). 
ET-1 failed to change the peak amplitude of It0 (9.3±4.6 and 9.0±4.4 pA/pF at +50 mV before 
and after ET-1, respectively, n=4, N.S.). The steady-state current-voltage relationship of the 
membrane was studied between -130 and 0 mV at the end of the 400-ms deporalization. At 
these potentials the current is most likely IK1. No change of this current (IKI) was noted after 
superfusion with 8 mmol/1 ET-1( fig. 23 ). Applying hyperpolarization to -100 mV, the IKI 
current densities were 3.6+1.4 and 3.7+1.4 and 3.7+1.4 pA/pF in control conditions and in the 
presence of ET-1, respectively (n=4, N.S.) 
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Fig. 23. Steady-state current-voltage relationship representing the inward rectifier potassium current I ki before 
and after administration of 8 nM endothelin-l(left). The steady state current-voltage relationship of the 
membrane was studied between -130 and 0 mV at the end of the 400 ms depolarisation (right). 
5. 3. 3. Effect ofET-1 on action potetial characteristics 
In multicellular left ventricular muscle preparations (n=3) paced at 1.2 Hz, ET-1 caused a 
moderate change in action potential morphology. Action potential duration, measured at 50 % 
of repolarization, was slightly increased (from 146+6 to 160+3 ms) by 8 nmol/1 ET-1. This 
effect was reverted by isoproterenol. Application of isoprotenol (50 nmol/1) in the presence of 
ET-1 shortened APD50 from 160+3 to 144+11 ms, a value close to the control level (fig. 24). 
34 
50 
> E 
« M 
C 
<D 
O 
CL 
0) 
c 
(Ü 
i _ 
43 
£ 
<13 
0 
- 5 0 -
-100-J 
ET-1 + 
Isoproterenol 
T 
0 
Control 
ET-1 
100 200 
Time (ms) 
300 
Fig. 24. Effect of endothelin-1 and isoproterenol on action potential configuration in a left ventricular trabecula. 
After control recordings, 8 nM endothelin-1 was applied for 15 min, then the preparation was exposed to 50 nM 
isoproterenol for an additional 15 min in the continuous presence of endothelin-1. 
The corresponding changes in APD90 were less pronounced (APD90 values of 213+7, 221+3 
and 209+7 ms were obtained in control, after application of ET-1, and in the presence of ET-1 
plus isoproterenol, respectively). ET-1 had no effect on the resting potential (-81.8+3.3 versus 
107.8+4.6 mV) and maximum rate of deporalization (215+33 versus 204+21 V/s), measured 
before and after superfusion with ET-1, respectively. 
6. DISCUSSION 
The homograft bank of the Department of Cardiac Surgery uses mainly beating heart 
donors for prepaing aortic and pulmonary human valvular conduits which are used for aortic 
valve replacement with aortic homografts or pulmonary autografts (Ross procedure). Since 
the myocardial mass of the explanted heart is otherwise destroyed after valvular conduit 
preparation, the purpose of this work was to preserve the undiseased myocardium and use 
parts of it for electrophysiological and pharmacological studies. This experimental protocol 
complied with the declaration of the World Medical Association proclaimed in Helsinki and 
was approved by the Ethical Review Board of the University of Szeged. ( No.: 51-57/1997 
Oej) 
To achieve this, the hearts were explanted according to the transplantation protocol 
(cold cardioplegic solution administrated into the aortic root after decompression of the heart 
and crossclamping of the aorta). The hearts were transported in cold (+4 °C) cardioplegic 
solution and both the isolated myocytes and the trabecular and papillary muscles were used 
for experiments within 5-12 hours after aortic crossclamping. With this method the mechanic 
and electrophysiologic properties of the myocardium were entirely preserved. 
The purpose of the first series of experiments was to examine the cellular 
electrophysiological effects of GYKI 16638, in comparison with sotalol and mexiletine, in 
isolated undiseased human ventricular muscle. The most important result of this study is that 
GYKI 16638, unlike sotalol, lengthened repolarization in a frequency independent manner, 
while like mexiletine, it decreased Vmax only at heart rates faster than the normal range.The 
two drugs, sotalol and mexiletine, which were used for comparison, were investigated 
previously on ventricular action potential in various mammalian heart preparations, including 
in some experiments on ventricular trabecular muscle obtained from explanted endstage heart 
failure human hearts (16), but the effects of these drugs on the action potential characteristics 
have never been established directly in undiseased human ventricular muscle. Sotalol, which 
has been classified as Class III antiarrhythmic drug (17), has been reported to lengthen APD 
in a reverse rate dependent manner without affecting Vmax (18). In this study we 
confirmed these earlier observations made in animal preparations and, in vivo clinical 
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electrophysiological measurements . Mexiletine, a drug which has been classified as a Class 
IB antiarrithmic drug (19) , according to earlier investigations performed also in animal 
preparations (20,21,22,4) and in vivo clinical electrophysiological measurements (23), 
shortened or did not change APD significantly, but induced Vmax block with fast recorvery 
kinetics (20). 
The effect of GYKI 16638 on the action potential and transmembrane ionic currents 
was studied in rabbit cardiac preparations. These results showed that GYKI 16638 lengthened 
APD and blocked Vmax in rabbit cardiac papillary muscle (24) and depressed the rapidly 
activating delayed rectifier potassium (IRT) and inward rectifier potassium (IKI) currents in 
rabbit ventricular myocytes (24). In addition, in dogs, rabbits and rats the compound exerted 
in vivo antiarrhytmic effect comparable to that sotalol (24). 
The purpose of the chemical synthesis of the GYKI compounds was to develop an 
antiarrhythmic drug, which would be devoid of the proarrhythmic potential of the selective 
Class III and Class I drugs, and does not exhibit serious extracardiac side effects.To achieve 
this latter goal, the chemical structure of GYKI does not resemble that of amiodarone, but 
shows similarities with the structure of both sotalol and mexiletine (figl). Combining Class 
IB and Class III antiarrhythmic effects was reported to attenuate reverse rate-dependent 
prolongation of APD and abolished EAD formation commonly seen after administration of 
pure Class HI drugs (4). It was also reported that erythromycin induced torsade de pointes 
arrhythmia was succesfully abolished with mexiletine in a patient (25). Although some 
clinical reports suggested strong antiarrhythmic effect of the combination of Class IB and 
Class HI drugs (26), no large scale clinical trial has been initiated to establish the real 
therapeutic value of such combination. 
Amiodarone, however, is a drug, which has strong antiarrhythmic efficacy in patients, 
while showing promising results regarding mortality in multicenter clinical trials (27). In 
addition, amiodarone treatment is associated with low incidence of proarrhytmic complication 
(6). Amiodarone, besides other effects, possesses strong rate-independent Class III and Class 
IB properties (28,29). These favourable effects of amiodarone can be, at least partly, 
attributed to its peculiar cellular electrophysiologic properties: strong rate dependent Vmax 
block with fast offset kinetics (28,29). Also, chronic amiodarone treatment lengthened 
repolarization rate-independently and decreased IRT density in rabbit ventricular muscle 
(28,30). It is important to note that both acute and chronic amiodarone administration 
abolished EAD formation in dog Purkinje fibers and M cells alike (28,31). This latter effect 
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can be attributed to the depression of the slowly inactivating (32), or window (33) sodium 
current, which would limit the undesirable consequence of IRT block, resulting in rate 
independent APD prolongation and minimal increase of dispersion of repolarization. Based 
on its cellular electrophysiological effects, a similar mechanism can be postulated with GYKI 
16638. 
The present study has, however, some possible limitations. We have applied only one 
drug concentration. Taking into consideration the diffusion barrier and the time course of the 
experiments, the selected drug concentrations were somewhat higher, but still close to the 
therapeutic plasma concentrations measured in patients with sotalol (34,3,35) and mexiletine 
(23,36) and established with GYKI 16638 (l-2pM) in pharmacokinetic investigations. Also, 
we applied only right ventricular endocardial preparations, which may not well represent the 
whole heart (37). These limitations are explained by the difficulty in obtaining human 
ventricular preparations for experimental purpose. 
The experiments made on isolated myocytes revealed the existence of IKs in 
undiseased human myocardium and like in the dog ventricle, it shows slow activation and 
relatively rapid deactivation kinetics. Earlier reports regarding existence of IRs in human 
ventricle were controversial. In some studies (38,39,40,41) no evidence was found for IRS 
activity. In a previous study (42) we could identity only IRT in human myocytes, but with 
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changing of the pipette solution (more free K , presence of HPO4 " and ADP) in the presence 
of IRT blocking agents, we recorded a tail current identified as IRS. Even so the current was 
present only in 31 out of 58 cells, in 27 cells it was either absent or too small to identify. This 
could be explained by the origin of the cells from diffenrent layers of the ventricular wall, 
thereby reflecting regional heterogeneity of the myocytes rather than technical reasons. 
Earlier experiments performed in the presence of IRT block and Ba CI2 an Cd CI2 , revealed tail 
currents similar to IRS (15). In our experiments tail currents appeared also when both IRS and 
IRT were blocked, in the presence of Ba CI2. This can be explained by the interaction of Ba2+ 
with IRI currents (43). IRs in cloned human KvLQTl+MinK channels expressed in COS cells 
(44) revealed similar properties with IRS in undiseased human myocardium, only with slower 
deactivation. The characteristics of IRS measured in our study show similarities with those 
reported in dog ( 4 5 , 4 6 ) and rabbit (47) hearts. 
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The results obtained from the experiments carried out on isolated human ventricular 
cells in the presence of ET-1 showed that endothelin suppresses both Ica-L and IKr, without 
affecting IT 0 and IRI. The IC3-L inhibition of ET-1 in human myocytes is similar to that 
obtained in studies on atrial and ventricular cells from rabbit and guinea pigs (10,12,48,13), 
and markedly differs from those obtained in rat atrial cells (49). The effects of ET-1 on 
potassium currents differ largely among species. ET-1 inhibitis IR in rat myocytes (50), 
activates it in guinea pig cells (51) and leaves it unaltered in canine heart cells. This latter 
results differ from those obtained in human ventricular cells, where IR, is markedly 
suppressed by ET-1. Ito and IRI remains unaltered, as in canine ventricular cells (unpublished 
results). The effects of ET-1 on APD are also controversial and show great differences among 
species. While in rabbit and guinea pig atrial cells (12) endothelin shortened APD, in human 
ventricular cells, 8 mmol/1, ET-1 moderately lenghtened APD (similar results were obtained 
in canine and rat ventricular cells). The ET-1 induced lengthening of APD is consistent with 
the inhibition of IRJ-and IcA-L-
7. CONCLUSIONS 
7.1. The explanation of hearts from beating heart donors for aortic and pulmonary 
homografts preparation according to the transplantation protocol, offers a great opportunity 
for electrophysiological and pharmacological studies on undiseased human myocardium 
which is otherwise destroyed after valvular conduit isolation. 
7.2. The study of the electrophysiological effects of sotalol, mexiletine and GYKI 16638 on 
human trabecular and papillary muscle preparations showed that GYKI 16638 has combined 
Class IB an m antiarrhythmic properties, similar to the electrophysiological effects seen after 
chronic amiodarone treatment. GYKI 16638 can therefore be a useful new antiarrhythmic 
drug candidate for further studies in animal experiments and also in patients. 
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7.3. The voltage clamp experiments on isolated human ventricular cells provided further 
evidence for the existence of IKS in human myocardium, with characteristics similar to IKS 
recorded in dog and rabbit myocytes. 
7.4. ET-1 slightly prolongs action potential duration by reducing the activity of IKT and Ica-L, 
without affecting It0 and IKI. These results help to elucidate the effects of ET-1 on human 
myocardium, which cannot be deduced from mammalian heart experiments, because of the 
marked interspecies differences. 
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